Last week was a strange mix.
Novo Nordisk CEO Lars Fruergaard Jørgensen was either "ousted" or "stepped down" or "replaced" in a "surprise move" after losing the edge to Eli Lilly. Here’s Karen Gilchrist's take in CNBC ('Novo Nordisk ousts CEO as Wegovy maker faces growing competition'):
"The decision comes as Novo Nordisk’s stock price has taken a batter…
Keep reading with a 7-day free trial
Subscribe to Hardcore Zen to keep reading this post and get 7 days of free access to the full post archives.